For research use only. Not for therapeutic Use.
MC4171(CAT: I040997) is a selective and reversible KAT8 (lysine acetyltransferase 8) inhibitor, with an IC₅₀ of 8.1 μM, making it a valuable tool for epigenetics and cancer research. It effectively reduces histone H4 lysine 16 acetylation (H4K16Ac) without affecting KAT8 expression or H3K27 acetylation, demonstrating high specificity. MC4171 shows moderate antiproliferative effects in non-small cell lung cancer (NSCLC) and acute myeloid leukemia (AML) while sparing non-transformed cells. With strong selectivity among lysine acetyltransferases and deacetylases, it is ideal for studying histone modifications and targeted cancer therapy development. For research use only; not for human or clinical applications.
| Catalog Number | I040997 |
| Synonyms | 4-[(4Z)-5-oxo-3-phenyl-4-(1H-pyrrol-2-ylmethylidene)pyrazol-1-yl]benzoic acid |
| Molecular Formula | C21H15N3O3 |
| Purity | ≥95% |
| IUPAC Name | 4-[(4Z)-5-oxo-3-phenyl-4-(1H-pyrrol-2-ylmethylidene)pyrazol-1-yl]benzoic acid |
| InChI | InChI=1S/C21H15N3O3/c25-20-18(13-16-7-4-12-22-16)19(14-5-2-1-3-6-14)23-24(20)17-10-8-15(9-11-17)21(26)27/h1-13,22H,(H,26,27)/b18-13- |
| InChIKey | XZSXRFQYJMTUKM-AQTBWJFISA-N |
| SMILES | C1=CC=C(C=C1)C2=NN(C(=O)C2=CC3=CC=CN3)C4=CC=C(C=C4)C(=O)O |
